obinutuzumab,acalabrutinib
roche,astrazeneca
['calquence', 'obinu', 'astrazeneca']
#astrazeneca reported #calquence plus #obinutuzumab demonstrated sustained survival benefit in 1st-line #chroniclymphocyticleukaemia with 90% of patients surviving five years in #elevatetn trial #asco22 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.